arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Minerva Neurosciences, Inc.

NERV
$3.53 ▼ -0.29 (-7.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Minerva Neurosciences, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $164.5M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC 3.9%
FCF / Share $-0.29
Trailing P/E 9.8x
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-125.40M
↓ -3241.5%
FCF / Share Free cash flow per share
$-0.29
↓ -131.7%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Cash Quality
24

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 55 quarters